The impact of comorbid atopic disease on asthma: Clinical expression and treatment

Journal of Asthma

Volumn 44, Issue 3, 2007, Pages 149-161

  Peters, Stephen ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Allergic rhinitis; Asthma; Atopy; IgE mediated inflammation; Omalizumab

Indexed keywords

ADALIMUMAB; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIHISTAMINIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CHEMOKINE; CORTICOSTEROID; CYTOKINE; ETANERCEPT; FC RECEPTOR; FLUTICASONE; FLUTICASONE PROPIONATE; IMMUNOGLOBULIN E; INFLIXIMAB; INTERLEUKIN 13; INTERLEUKIN 13 ANTIBODY; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 9; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONOCLONAL ANTIBODY; MONTELUKAST; NITRIC OXIDE; OMALIZUMAB; PLACEBO; POLYCLONAL ANTIBODY; SUPLATAST TOSYLATE; UNINDEXED DRUG; ZAFIRLUKAST; ZILEUTON;

ALLERGIC ASTHMA; ALLERGIC RHINITIS; ANKYLOSING SPONDYLITIS; ANTIINFLAMMATORY ACTIVITY; ATOPIC DERMATITIS; ATOPY; B LYMPHOCYTE; BRONCHUS HYPERREACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMORBIDITY; COMPLEMENT SYSTEM; CORTICOSTEROID THERAPY; CROHN DISEASE; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG MECHANISM; EOSINOPHIL; EPIDEMIOLOGICAL DATA; HAY FEVER; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; LOWER RESPIRATORY TRACT; MAST CELL; NERVOUS SYSTEM; NONHUMAN; PARANASAL SINUS; PATHOPHYSIOLOGY; PSORIASIS; QUALITY OF LIFE; RESPIRATORY TRACT INFLAMMATION; REVIEW; RHEUMATOID ARTHRITIS; RHINOSINUSITIS; SIGNAL TRANSDUCTION; SINUSITIS; TH2 CELL; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT; VIRUS INFECTION;

ANTI-ASTHMATIC AGENTS; ASTHMA; DERMATITIS, ATOPIC; HUMANS; HYPERSENSITIVITY; PREVALENCE; RHINITIS; SINUSITIS; UNITED STATES;

EID: 34247160890     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.1080/02770900600925478     Document Type: Review

References (161)

1. Schramm B, Ehlken B, Smala A, Quednau K, Berger K, Nowak D. Cost of illness of atopic asthma and seasonal allergic rhinitis in Germany: 1-yr retrospective study. Eur Respir J 2003; 21:116-122.
2. Bousquet J, Van Cauwenberge P, Khaltaev N; for the ARIA Workshop Group and the World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108(5 suppl):S147-S334.
3. Centers for Disease Control: National Center for Health Statistics. Summary Health Statistics for U. S. Adults: National Health Interview Survey, 2003. Available at: http://www. cdc.gov. Accessed May 8, 2006.
4. Greisner WA 3rd, Settipane RJ, Settipane GA. Co-existence of asthma and allergic rhinitis: a 23-year follow-up study of college students. Allergy Asthma Proc 1998; 19:185-188.
5. Mullarkey MF, Hill JS, Webb DR. Allergic and nonallergic rhinitis: their characterization with attention to the meaning of nasal eosinophilia. J Allergy Clin Immunol 1980; 65:122-126.
6. Malo JL, Lemiere C, Desjardins A, Cartier A. Prevalence and intensity of rhinoconjunctivitis in subjects with occupational asthma. Eur Respir J 1997; 10:1513-1515.
7. Leynaert B, Neukirch C, Kony S, Guenegou A, Bousquet J, Aubier M, Neukirch F. Association between asthma and rhinitis according to atopic sensitization in a population-based study. J Allergy Clin Immunol 2004; 113:86-93.
8. Linneberg A, Henrik Nielsen N, Frolund L, Madsen F, Dirksen A, Jorgensen T, for the Copenhagen Allergy Study. The link between allergic rhinitis and allergic asthma: a prospective population-based study. Allergy 2002; 57:1048-1052.
9. Holgate ST, Chuchalin AG, Hebert J, Lotvall J, Persson GB, Chung KF, et al., for the Omalizumab 011 International Study Group. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004; 34:632-638.
10. Soler M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18:254-261.
11. Reicin A, White R, Weinstein SF, Finn AF Jr, Nguyen H, Peszek I, et al. Montelukast, a leukotriene receptor antagonist, in combination with loratadine, a histamine receptor antagonist, in the treatment of chronic asthma. Arch Intern Med 2000; 160:2481-2488.
12. Leynaert B, Bousquet J, Neukirch C, Liard R, Neukirch F. Perennial rhinitis: An independent risk factor for asthma in nonatopic subjects: results from the European Community Respiratory Health Survey. J Allergy Clin Immunol 1999; 104(2 Pt 1):301-304.
13. Settipane RJ, Hagy GW, Settipane GA. Long-term risk factors for developing asthma and allergic rhinitis: a 23-year follow-up study of college students. Allergy Proc 1994;15:21-25.
14. Guerra S, Sherrill DL, Martinez FD, Barbee RA. Rhinitis as an independent risk factor for adult-onset asthma. J Allergy Clin Immunol 2002; 109:419-425.
15. Wright AL, Holberg CJ, Martinez FD, Halonen M, Morgan W, Taussig LM. Epidemiology of physician-diagnosed allergic rhinitis in childhood. Pediatrics 1994; 94(6 Pt 1):895-901.
16. Arrighi HM, Maier WC, Redding GJ, Morray BH, Llewellyn CE. The impact of allergic rhinitis in Seattle school children [abstr]. J Allergy Clin Immunol 1995; 95:192.
17. Masuda S, Fujisawa T, Katsumata H, Atsuta J, Iguchi K, Kamiya H. Nasal symptoms in children with bronchial asthma [abstr]. J Allergy Clin Immunol 2003; 111:S138.
18. Passalacqua G, Ciprandi G, Pasquali M, Guerra L, Cononica GW. An update on the asthma-rhinitis link. Curr Opin Allergy Clin Immunol 2004; 4:177-183.
19. Dykewicz MS, Fineman S, Skoner DP, Nicklas R, Lee R, Blessing-Moore J, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 1998; 81:478-518.
20. Leynaert B, Neukirch F, Demoly P, Bousquet J. Epidemiologic evidence for asthma and rhinitis comorbidity. J Allergy Clin Immunol 2000; 106:S201-S205.
21. ten Brinke A, Grootendorst DC, Schmidt JT, De Bruine FT, van Buchem MA, Sterk PJ, et al. Chronic sinusitis in severe asthma is related to sputum eosinophilia. J Allergy Clin Immunol 2002; 109:621-626.
22. Bresciani M, Paradis L, Des Roches A, Vernhet H, Vachier I, Godard P, et al. Rhinosinusitis in severe asthma. J Allergy Clin Immunol 2001; 107:73-80.
23. Rachelefsky GS, Goldberg M, Katz RM, Boris G, Gyepes MT, Shapiro MJ, et al. Sinus disease in children with respiratory allergy. J Allergy Clin Immunol 1978; 61:310-314.
24. Savolainen S. Allergy in patients with acute maxillary sinusitis. Allergy 1989; 44:116-122.
25. Harlin SL, Ansel DG, Lane SR, Myers J, Kephart GM, Gleich GJ. A clinical and pathologic study of chronic sinusitis: the role of the eosinophil. J Allergy Clin Immunol 1988; 81(5 Pt 1):867-875.
26. Wahn U, von Mutius E. Childhood risk factors for atopy and the importance of early intervention. J Allergy Clin Immunol 2001; 107:567-574.
27. Gustafsson D, Sjoberg O, Foucard T. Development of allergies and asthma in infants and young children with atopic dermatitis - a prospective follow-up to 7 years of age. Allergy 2000; 55:240-245.
28. Bergmann RL, Edenharter G, Bergmann KE, Forster J, Bauer CP, Wahn V, et al. Atopic dermatitis in early infancy predicts allergic airway disease at 5 years. Clin Exp Allergy 1998; 28:965-970.
29. Illi S, von Mutius E, Lau S, Nickel R, Gruber C, Niggemann B, et al., for the Multicenter Allergy Study Group. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. J Allergy Clin Immunol 2004; 113:925-931.
30. Luskin AT, Scherger JE, Pollart SM. Beyond the nose: the systemic inflammatory effects of allergic rhinitis. Hosp Physician 2004; 13-22.
31. Gelfand E. Inflammatory mediators in allergic rhinitis. J Allergy Clin Immunol 2004; 114(5):S135-S138.
32. Corren J, Adinoff AD, Irvin CG. Changes in bronchial responsiveness following nasal provocation with allergen. J Allergy Clin Immunol 1992; 89:611-618.
33. Windom HH, Lim-Monbay M, Thompson M, Naclerio RM, Togias A. The effect of nasal versus bronchial antigens (Ag) challenge on the asthmatic airways [abstr]. J Allergy Clin Immunol 1992; 9:334.
34. Noureddine G, Thompson M, Brennan F, Proud D, Kagey-Sobotka A, Lichtenstein LM, et al. Nasal antigen challenge in asthmatics: effects of cetirizine on nasal and pulmonary responses [abstr]. J Allergy Clin Immunol 1994; 3:177.
35. Braunstahl GJ, Overbeek SE, Kleinjan A, Prins JB, Hoogsteden HC, Fokkens WJ. Nasal allergen provocation induces adhesion molecule expression and tissue eosinophilia in upper and lower airways. J Allergy Clin Immunol 2001; 107:469-476.
36. Braunstahl GJ, Kleinjan A, Overbeek SE, Prins JB, Hoogsteden HC, Fokkens WJ. Segmental bronchial provocation induces nasal inflammation in allergic rhinitis patients. Am J Respir Crit Care Med 2000; 161:2051-2057.
37. Pelikan Z, Pelikan-Filipek M. Role of nasal allergy in chronic maxillary sinusitis-diagnostic value of nasal challenge with allergen. J Allergy Clin Immunol 1990; 86:484-491.
38. Baroody FM, deTineo M, Haney L, Clark K, Blair C, Naclerio RM. Influx of eosinophils into the maxillary sinus after nasal challenge with allergen [abstr]. J Allergy Clin Immunol 2000; 105(suppl):S70-S71.
39. Adkins TN, Goodgold HM, Hendershott L, Slavin RG. Does inhaled pollen enter the sinus cavities? Ann Allergy Asthma Immunol 1998; 81:181-184.
40. Baroody FM, Saengpanich S, deTineo M, Haney L, Votypka V, Naclerio RM. Nasal allergen challenge leads to bilateral maxillary sinus eosinophil influx [abstr]. J Allergy Clin Immunol 2002; 109(suppl):S84.
41. Keller R. Dendritic cells: their significance in health and disease. Immunol Lett 2001; 78:113-122.
42. Purkerson JM, Isakson PC. Interleukin 5 (IL-5) provides a signal that is required in addition to IL-4 for isotype switching to immunoglobulin (Ig) G1 and IgE. J Exp Med 1992; 175: 973-982.
43. Punnonen J, Aversa G, Cocks BG, McKenzie AN, Menon S, Zurawski G, et al. Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells. Proc Natl Acad Sci USA 1993; 90:3730-3734.
44. Ferreira MA. Inflammation in allergic asthma: initiating events, immunological response and risk factors. Respirology 2004; 9:16-24.
45. Buckley MG, Williams CM, Thompson J, Pryor P, Ray K, Butterfield JH, et al. IL-4 enhances IL-3 and IL-8 gene expression in a human leukemic mast cell line. Immunology 1995; 84:410-415.
46. Toru H, Ra C, Nonoyama S, Suzuki K, Yata J, Nakahata T. Induction of the high-affinity IgE receptor (Fc epsilon RI) on human mast cells by IL-4. Int Immunol 1996; 8:1367-1373.
47. Mosmann TR, Bond MW, Coffman RL, Ohara J, Paul WE. T-cell and mast cell lines respond to B-cell stimulatory factor 1. Proc Natl Acad Sci USA 1986; 83:5654-5658.
48. Xia HZ, Du Z, Craig S, Klisch G, Noben-Trauth N, Kochan JP, et al. Effect of recombinant IL-4 on tryptase, chymase, and Fc epsilon receptor type 1 expression in recombinant human stem cell factor-dependent fetal liver-derived human mast cells. J Immunol 1997; 159:2911-2921.
49. Saini S, Bloom DC, Bieneman A, Vasagar K, Togias A, Schroeder J. Systemic effects of allergen exposure on blood basophil IL-13 secretion and FcepsionRIbeta. J Allergy Clin Immunol 2004; 114:768-774.
50. Wood LJ, Inman MD, Watson RM, Foley R, Denburg JA, O'Byrne PM. Changes in bone marrow inflammatory cell progenitors after inhaled allergen in asthmatic subjects. Am J Respir Crit Care Med 1998; 157:99-105.
51. Sehmi R, Wood LJ, Watson R, Foley R, Hamid Q, O'Byrne PM, et al. Allergen-induced increases in IL-5 receptor alpha-subunit expression on bone marrow-derived CD34+ cells from asthmatic subjects. A novel marker of progenitor cell commitment towards eosinophilic differentiation. J Clin Invest 1997; 100:2466-2475.
52. Gibson PG, Manning PJ, O'Byrne PM, Girgis-Gabardo A, Dolovich J, Denburg JA, et al. Allergen-induced asthmatic responses. Relationship between increases in airway responsiveness and increases in circulating eosinophils, basophils, and their progenitors. Am Rev Respir Dis 1991; 143:331-335.
53. Dorman SC, Babirad I, Post J, Watson RM, Foley R, Jones GL, et al. Progenitor egress from the bone marrow after allergen challenge: role of stromal cell-derived factor 1alpha and eotaxin. J Allergy Clin Immunol 2005; 115:501-507.
54. Wood LJ, Sehmi R, Gauvreau GM, Watson RM, Foley R, Denburg JA, et al. An inhaled corticosteroid, budesonide, reduces baseline but not allergen-induced increases in bone marrow inflammatory cell progenitors in asthmatic subjects. Am J Respir Crit Care Med 1999; 159(5 Pt 1):1457-1463.
55. Shen H, O'Byrne PM, Ellis R, Wattie J, Tung C, Inman MD. The effects of intranasal budesonide on allergen-induced production of interleukin-5 and eotaxin, airways, blood, and bone marroweosinophilia, and eosinophil progenitor expansion in sensitized mice. Am J Respir Crit Care Med 2002; 166:146-153.
56. Sergejeva S, Malmhall C, Lotvall J, Pulleritis T. Increased number of CD34+ cells in nasal mucosa of allergic rhinitis patients: inhibition by a local corticosteroid. Clin Exp Allergy 2005; 35:34-38.
57. Baroody FM, Wagenmann M, Naclerio RM. Comparison of the secretory response of the nasal mucosa to methacholine and histamine. J Appl Physiol 1993; 74:2661-2671.
58. Sanico AM, Philip G, Lai GK, Togias A. Hyperosmolar saline induces reflex nasal secretions, evincing neural hyperresponsiveness in allergic rhinitis. J Appl Physiol 1999; 86:1202-1210.
59. Riccio, MM, Proud D. Evidence that enhanced nasal reactivity to bradykinin in patients with symptomatic allergy is mediated by neural reflexes. J Allergy Clin Immunol 1996; 97:1252-1263.
60. Fontanari P, Burnet H, Zattara-Hartmann MC, Jammes Y. Changes in airway resistance induced by nasal inhalation of cold dry, dry, or moist air in normal individuals. J Appl Physiol 1996; 81:1739-1743.
61. Nieber K, Baumgarten CR, Rathsack R, Furkert J, Oehme P, Kunkel G. Substance P and beta-endorphin-like immunoreactivity in lavage fluids of subjects with and without allergic asthma. J Allergy Clin Immunol 1992; 90(4 Pt 1):646-652.
62. Heaney LG, Cross LJ, Ennis M. Histamine release from bronchoalveolar lavage cells from asthmatic subjects after allergen challenge and relationship to the late asthmatic response. Clin Exp Allergy 1998;28:196-204.
63. Undem BJ, McAlexander M, Hunter DD. Neurobiology of the upper and lower airways. Allergy 1999; 54(suppl 57):81-93.
64. Togias A. Rhinitis and asthma: evidence for respiratory system integration. J Allergy Clin Immunol 2003; 111:1171-1183.
65. Griffin MP, McFadden ER Jr, Ingram RH Jr. Airway cooling in asthmatic and nonasthmatic subjects during nasal and oral breathing. J Allergy Clin Immunol 1982; 69:354-359.
66. Koh YY, Kim CK. The development of asthma in patients with allergic rhinitis. Curr Opin Allergy Clin Immunol 2003; 3:159-164.
67. Gleeson K, Eggli DF, Maxwell SL. Quantitative aspiration during sleep in normal subjects. Chest 1997; 111:1266-1272.
68. Ferreira A, Williams Z, Donninger H, van Schalkwyk EM, Bardin PG. Rhinovirus is associated with severe asthma exacerbations and raised nasal interleukin-12. Respiration 2002; 69:136-142.
69. Henriksen JM, Wenzel A. Effect of an intranasally administered corticosteroid (budesonide) on nasal obstruction, mouth breathing, and asthma. Am Rev Respir Dis 1984; 130:1014-1018.
70. Watson WT, Becker AB, Simons FE. Treatment of allergic rhinitis with intranasal corticosteroids in patients with mild asthma: effect on lower airway responsiveness. J Allergy Clin Immunol 1993; 91(1 Pt 1):97-101.
71. Welsh PW, Stricker WE, Chu CP, Naessens JM, Reese ME, Reed CE, et al. Efficacy of beclomethasone nasal solution, flunisolide, and cromolyn in relieving symptoms of ragweed allergy. Mayo Clin Proc 1987; 62:125-134.
72. Adams RJ, Fuhlbrigge AL, Finkelstein JA, Weiss ST. Intranasal steroids and the risk of emergency department visits for asthma. J Allergy Clin Immunol 2002; 109:636-642.
73. Crystal-Peters J, Neslusan C, Crown WH, Torres A. Treating allergic rhinitis in patients with comorbid asthma: the risk of asthma-related hospitalizations and emergency department visits. J Allergy Clin Immunol 2002; 109:57-62.
74. Corren J, Adinoff AD, Buchmeier AD, Irvin CG. Nasal beclomethasone prevents the seasonal increase in bronchial responsiveness in patients with allergic rhinitis and asthma. J Allergy Clin Immunol 1992; 90:250-256.
75. Berger WE, Schenkel EJ, Mansfield LE, for the Desloratadine Study Group. Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion. Ann Allergy Asthma Immunol 2002; 89:485-491.
76. Senior BA, Kennedy DW, Tanabodee J, Kroger H, Hassab M, Lanza DC. Long-term impact of functional endoscopic sinus surgery on asthma. Otolaryngol Head Neck Surg 1999; 121:66-68.
77. Dunlop G, Scadding GK, Lund VJ. The effect of endoscopic sinus surgery on asthma: management of patients with chronic rhinosinusitis, nasal polyposis, and asthma. Am J Rhinol 1999; 13:261-265.
78. Ikeda K, Tanno N, Tamura G, Suzuki H, Oshima T, Shimomura A, et al. Endoscopic sinus surgery improves pulmonary function in patients with asthma associated with chronic sinusitis. Ann Otol Rhinol Laryngol 1999; 108:355-359.
79. Tosca MA, Cosentino C, Pallestrini E, Caligo G, Milanese M, Ciprandi G. Improvement of clinical and immunopathologic parameters in asthmatic children treated for concomitant chronic rhinosinusitis. Ann Allergy Asthma Immunol 2003; 91:71-78.
80. Tsao CH, Chen LC, Yeh KW, Huang JL. Concomitant chronic sinusitis treatment in children with mild asthma: the effect on bronchial hyperresponsiveness. Chest 2003; 123:757-764.
81. Smurthwaite L, Durham SR. Local IgE synthesis in allergic rhinitis and asthma. Curr Allergy Asthma Rep 2002; 2:231-238.
82. Pawankar R, Yamagishi S, Yagi T. Revisiting the roles of mast cells in allergic rhinitis and its relation to local IgE synthesis. Am J Rhinol 2000; 14:309-317.
83. Sherrill DL, Stein R, Halonen M, Holberg CJ, Wright A, Martinez FD. Total serum IgE and its association with asthma symptoms and allergic sensitization among children. J Allergy Clin Immunol 1999; 104:28-36.
84. Platts-Mills TA. The role of immunoglobulin E in allergy and asthma. Am J Respir Crit Care Med 2001; 164(8 Pt 2):S1-S5.
85. Skoner DP. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol 2001; 108:S2-S8.
86. Rajakulasingam K, Till S, Ying S, Humbert M, Barkans J, Sullivan M, et al. Increased expression of high affinity IgE (FcepsilonRI) receptor-alpha chain mRNA and protein-bearing eosinophils in human allergen-induced atopic asthma. Am J Respir Crit Care Med 1998; 158:233-240.
87. Pawankar R, Okuda M, Yssel H, Okumura K, Ra C. Nasal mast cells in perennial allergic rhinitics exhibit increased expression of the Fc epsilonRI, CD40 L, IL-4, and IL-13, and can induce IgE synthesis in B cells. J Clin Invest 1997; 99:1492-1499.
88. Yamaguchi M, Lantz CS, Oettgen HC, Katona IM, Fleming T, Miyajima I, et al. IgE enhances mouse mast cell Fc(epsilon)RI expression in vitro and in vivo: evidence for a novel amplification mechanism in IgE-dependent reactions. J Exp Med 1997; 185:663-672.
89. Ong YE, Menzies-Gow A, Barkans J, Benyahia F, Ou TT, Ying S, et al. Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge. J Allergy Clin Immunol 2005; 116:558-564.
90. Lin H, Boesel KM, Griffith DT, Prussin C, Foster B, Romero FA, et al. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. J Allergy Clin Immunol 2004; 113:297-302.
91. Prussin C, Griffith DT, Boesel KM, Lin H, Foster B, Casale TB. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol 2003; 112:1147-1154.
92. Beck LA, Marcotte GV, MacGlashan D, Togias A, Saini S. Omalizumab-induced reductions in mast cell Fcepsilon RI expression and function. J Allergy Clin Immunol 2004; 114:527-530.
93. Djukanovic R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004; 170:583-593.
94. Noga O, Hanf G, Kunkel G. Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. Int Arch Allergy Immunol 2003; 131:46-52.
95. Plewako H, Arvidsson M, Petruson K, Oancea I, Holmberg K, Adelroth E, et al. The effect of omalizumab on nasal allergic inflammation. J Allergy Clin Immunol 2002; 110:68-71.
96. Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004; 59;701-708.
97. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108:184-190.
98. Lanier BQ, Corren J, Lumry W, Lui J, Fowler-Taylor A, Gupta N. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol 2003; 91:154-159.
99. Buhl R, Soler M, Matz J, Townley R, O'Brien J, Noga O, et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J 2002; 20:73-78.
100. Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004; 59:709-717.
101. Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005; 60:302-308.
102. Adelroth E, Rak S, Haahtela T, Aasand G, Rosenhall L, Zetterstrom O, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000; 106:253-259.
103. Casale TB, Condemi J, LaForce C, Nayak A, Rowe M, Watrous M, et al., for the Omalizumab Seasonal Allergic Rhinitis Trail Group. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA 2001; 286:2956-2967.
104. Nayak A, Casale T, Miller SD, Condemi J, McAlary M, Fowler-Taylor A, et al. Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis. Allergy Asthma Proc 2003; 24:323-329.
105. Chervinsky P, Casale T, Townley R, Tripathy I, Hedgecock S, Fowler-Taylor A, et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2003; 91:160-167.
106. Casale TB, Busse W. W, Kline JN Ballas ZK, Moss MH, Townley RG, et al., for the Immune Tolerance Network Group. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2006; 117:134-140.
107. National Asthma Education and Prevention Program (NAEPP). Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma. Update on Selected Topics 2002. Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute; 2003. NIH publication 02-5074.
108. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Bethesda, MD: National Institutes of Health, National Heart, Lung and Blood Institute; 2004. NIH publication 02-3659.
109. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999; 340:197-206.
110. Busse W, Kraft M. Cysteinyl leukotrienes in allergic inflammation: strategic target for therapy. Chest 2005; 127:1312-1326.
111. Ducharme FM, Di Salvio F. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev 2004; CD002314.
112. Ducharme F, Schwartz Z, Hicks G, Kakuma R. Addition of anti-leukotriene agents to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev 2004; (2):CD003133.
113. Wilson AM, O'Byrne PM, Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am J Med 2004; 116:338-344.
114. Philip G, Nayak AS, Berger WE, Leynadier F, Vrijens F, Dass SB, et al. The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis. Curr Med Res Opin 2004; 20:1549-1558.
115. Wilson AM, Orr LC, Sims EJ, Dempsey OJ, Lipworth BJ. Antiasthmatic effects of mediator blockade versus topical corticosteroids in allergic rhinitis and asthma. Am J Respir Crit Care Med 2000; 162(4 Pt 1):1297-1301.
116. Wilson AM, Sims EJ, Orr LC, Coutie WJ, White PS, Gardiner Q, et al. Effects of topical corticosteroid and combined mediator blockade on domiciliary and laboratory measurements of nasal function in seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2001; 87:344-349.
117. Tamaoki J, Kondo M, Sakai N, Aoshiba K, Tagaya E, Nakata J, et al. Effect of suplatast tosilate, a Th2 cytokine inhibitor, on steroid-dependent asthma: a double-blind randomised study. Tokyo Joshi-Idai Asthma Research Group. Lancet 2000; 356(9226):273-278.
118. Yoshida M, Aizawa H, Inoue H, Matsumoto K, Koto H, Komori M, et al. Effect of suplatast tosilate on airway hyperresponsiveness and inflammation in asthma patients. J Asthma 2002; 39:545-552.
119. Sano Y, Suzuki N, Yamada H, To Y, Ogawa C, Ohta K, et al. Effects of suplatast tosilate on allergic eosinophilic airway inflammation in patients with mild asthma. J Allergy Clin Immunol 2003; 111:958-966.
120. Hoshino M, Fujita Y, Saji J, Inoue T, Nakagawa T, Miyazawa T. Effect of suplatast tosilate on goblet cell metaplasia in patients with asthma. Allergy 2005; 60:1394-1400.
121. Furukido K, Takeno S, Ueda T, Hirakawa K, Yajin K. Suppression of the Th2 pathway by suplatast tosilate in patients with perennial nasal allergies. Am J Rhinol 2002; 16:329-336.
122. Woerly G, Decot V, Loiseau S, Loyens M, Chihara J, Ono N, et al. CD28 and secretory immunoglobulin A-dependent activation of eosinophils: inhibition of mediator release by the anti-allergic drug, suplatast tosilate. Clin Exp Allergy 2004; 34:1379-1387.
123. Yang G, Volk A, Petley T, Emmell E, Giles-Komar J, Shang X, et al. Anti-IL-13 monoclonal antibody inhibits airway hyperresponsiveness, inflammation and airway remodeling. Cytokine 2004; 28:224-232.
124. Yang G, Li L, Volk A, Emmell E, Petley T, Giles-Komar J, et al. Therapeutic dosing with anti-interleukin-13 monoclonal antibody inhibits asthma progression in mice. J Pharmacol Exp Ther 2005; 313:8-15.
125. Wang Y, McCusker CT. Interleukin-13-dependent bronchial hyperresponsiveness following isolated upper-airway allergen challenge in a murine model of allergic rhinitis and asthma. Clin Exp Allergy 2005; 35:1104-1111.
126. Hauber HP, Bergeron C, Hamid Q. IL-9 in allergic inflammation. Int Arch Allergy Immunol 2004; 134:79-87.
127. Erpenbeck VJ, Hohlfeld JM, Discher M, Krentel H, Hagenberg A, Braun A, et al. Increased expression of Interleukin-9 messenger RNA after segmental allergen challenge in allergic asthmatics. Chest 2003; 123(3 suppl):370 S.
128. Nouri-Aria KT, Pilette C, Jacobson MR, Watanabe H, Durham SR. IL-9 and c-Kit+mast cells in allergic rhinitis during seasonal allergen exposure: effect of immunotherapy. J Allergy Clin Immunol 2005; 116:73-79.
129. Cheng G, Arima M, Honda K, Hirata H, Eda F, Yoshida N, et al. Antiinterleukin-9 antibody treatment inhibits airway inflammation and hyperreactivity in mouse asthma model. Am J Respir Crit Care Med 2002; 166:409-416.
130. Sitkauskiene B, Radinger M, Bossios A, Johansson AK, Sakalauskas R, Lotvall J. Airway allergen exposure stimulates bone marrow eosinophilia partly via IL-9. Respir Res 2005; 6:33.
131. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn's Disease. N Engl J Med 2004; 350:876-885.
132. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, et al., for the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004; 50:1051-1065.
133. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359(9313):1187-1193.
134. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, et al., for the IMPACT 2 Trial Investigators. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005; 64:1150-1157.
135. Bradding P, Roberts JA, Britten KM, Montefort S, Djukanovic R, Mueller R, et al. Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol 1994; 10:471-480.
136. Gordon JR, Galli SJ. Release of both preformed and newly synthesized tumor necrosis factor alpha (TNF-α)/cachectin by mouse mast cells stimulated via the Fc epsilon RI. A mechanism for the sustained action of mast cell-derived TNF-α during IgE-dependent biological responses. J Exp Med 1991; 174:103-107.
137. Bensch GW, Nelson HS, Borish LC. Evaluation of cytokines in nasal secretions after nasal antigen challenge: lack of influence of antihistamines. Ann Allergy Asthma Immunol 2002; 88:457-462.
138. Kim J, McKinley L, Natarajan S, Bolgos GL, Siddiqui J, Copeland S, et al. Anti-tumor necrosis factor-alpha antibody treatment reduces pulmonary inflammation and methacholine hyper-responsiveness in a murine asthma model induced by house dust. Clin Exp Allergy 2006; 36:122-132.
139. Rouhani FN, Meitin CA, Kaler M, Miskinis-Hilligoss D, Stylianou M, Levine SJ. Effect of tumor necrosis factor antagonism on allergen-mediated asthmatic airway inflammation. Respir Med 2005; 99:1175-1182.
140. Laberge S, Ernst P, Ghaffar O, Cruikshank WW, Kornfeld H, Center DM, et al. Increased expression of interleukin-16 in bronchial mucosa of subjects with atopic asthma. Am J Respir Cell Mol Biol 1997; 17:193-202.
141. Cruikshank WW, Long A, Tarpy RE, Kornfeld H, Carroll MP, Teran L, et al. Early identification of interleukin-16 (lymphocyte chemoattractant factor) and macrophage inflammatory protein 1 alpha (MIP1 alpha) in bronchoalveolar lavage fluid of antigen-challenged asthmatics. Am J Respir Cell Mol Biol 1995; 13:738-747.
142. Krug N, Cruikshank WW, Tschernig T, Erpenbeck VJ, Balke K, Hohlfeld JM, et al. Interleukin 16 and T-cell chemoattractant activity in bronchoalveolar lavage 24 hours after allergen challenge in asthma. Am J Respir Crit Care Med 2000; 162:105-111.
143. Mashikian MV, Tarpy RE, Saukkonen JJ, Lim KG, Fine GD, Cruikshank WW, et al. Identification of IL-16 as the lymphocyte chemotactic activity in the bronchoalveolar lavage fluid of histamine-challenged asthmatic patients. J Allergy Clin Immunol 1998; 101(6 Pt 1):786-792.
144. Karaki M, Dobashi H, Kobayashi R, Tokuda M, Ishida T, Mori N. Expression of interleukin-16 in allergic rhinitis. Int Arch Allergy Immunol 2005; 138:67-72.
145. De Bie JJ, Jonker EH, Henricks PA, Hoevenaars J, Little FF, Cruikshank WW, et al. Exogenous interleukin-16 inhibits antigen-induced airway hyper-reactivity, eosinophilia and Th2-type cytokine production in mice. Clin Exp Allergy 2002; 32:1651-1658.
146. Burkart KM, Barton SJ, Holloway JW, Yang IA, Cakebread JA, Cruikshank W, et al. Association of asthma with a functional promoter polymorphism in the IL16 gene. J Allergy Clin Immunol 2006; 117:86-91.
147. Bautsch W, Hoymann HG, Zhang Q, Meier-Wiedenbach I, Raschke U, Ames RS, et al. Cutting edge: guinea pigs with a natural C3 a-receptor defect exhibit decreased bronchoconstriction in allergic airway disease: evidence for an involvement of the C3 a anaphylatoxin in the pathogenesis of asthma. J Immunol 2000; 165:5401-5405.
148. Drouin SM, Corry DB, Hollman TJ, Kildsgaard J, Wetsel RA. Absence of the complement anaphylatoxin C3 a receptor suppresses Th2 effector functions in a murine model of pulmonary allergy. J Immunol 2002; 169:5926-5933.
149. Humbles AA, Lu B, Nilsson CA, Lilly C, Israel E, Fujiwara Y, et al. A role for the C3 a anaphylatoxin receptor in the effector phase of asthma. Nature 2000; 406(6799):998-1001.
150. Taube C, Rha YH, Takeda K, Park JW, Joetham A, Balhorn A, et al. Inhibition of complement activation decreases airway inflammation and hyperresponsiveness. Am J Respir Crit Care Med 2003; 168:1333-1341.
151. Karp CL, Grupe A, Schadt E, Ewart SL, Keane-Moore M, Cuomo PJ, et al. Identification of complement factor 5 as a susceptibility locus for experimental allergic asthma. Nat Immunol 2000; 1:221-226.
152. Krug N, Tschernig T, Erpenbeck VJ, Hohlfeld JM, Kohl J. Complement factors C3 a and C5 a are increased in bronchoalveolar lavage fluid after segmental allergen provocation in subjects with asthma. Am J Respir Crit Care Med 2001; 164(10 Pt 1):1841-1843.
153. Fregonese L, Swan FJ, van Schadewijk A, Dolhnikoff M, Santos MA, Daha MR, et al. Expression of the anaphylatoxin receptors C3aR and C5aR is increased in fatal asthma. J Allergy Clin Immunol 2005; 115:1148-1154.
154. Baelder R, Fuchs B, Bautsch W, Zwirner J, Kohl J, Hoymann HG, et al. Pharmacological targeting of anaphylatoxin receptors during the effector phase of allergic asthma suppresses airway hyperresponsiveness and airway inflammation. J Immunol 2005; 174:783-789.
155. Crossman LC, O'Brien SG. Imatinib therapy in chronic myeloid leukemia. Hematol Oncol Clin North Am 2004; 18:605-617.
156. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295:139-145.
157. Berlin AA, Lukacs NW. Treatment of cockroach allergen asthma model with imatinib attenuates airway responses. Am J Respir Crit Care Med 2005; 171:35-39.
158. Meltzer EO, Berkowitz RB, Grossbard EB. An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment. J Allergy Clin Immunol 2005; 115:791-796.
159. Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 2002; 29(1 suppl 2):2-9.
160. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350:2572-2581.
161. Togias A. Systemic effects of local allergic disease. J Allergy Clin Immunol 2004; 113:S8-S14.